Today: 16 May 2026
Browse Category

NASDAQ:P3H 15 May 2026

P3 Health Partners turns profit in Q1, lifts 2026 forecast

P3 Health Partners turns profit in Q1, lifts 2026 forecast

P3 Health Partners shares surged over 200% to $13.00 Friday after the company posted its first quarterly profit and raised its 2026 adjusted EBITDA outlook. Net income reached $3 million versus a $44.2 million loss a year earlier, with revenue up 4% to $386 million despite a 10% drop in at-risk membership. The company cited $17 million in one-time benefits, leaving underlying adjusted EBITDA at $8 million.
15 May 2026
··

Stock Market Today

  • Synergy CHC Files S-1 for Resale and $36M Equity Line
    May 15, 2026, 6:07 PM EDT. Synergy CHC Corp. filed a Form S-1 registration with the U.S. Securities and Exchange Commission on May 15, 2026, for a proposed resale of securities and a $36 million equity line of credit. The filing, under the Securities Act of 1933, aims to facilitate the company's ability to raise capital through public offerings on a delayed or continuous basis as permitted by Rule 415. Synergy CHC, incorporated in Nevada and headquartered in Maine, is classified as a non-accelerated filer, reflecting smaller market capitalization. The equity line is expected to provide liquidity and support the company's growth initiatives, with offerings commencing once the registration becomes effective.

Latest articles

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

15 May 2026
Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
AXT delays annual meeting to June after AI-driven stock jump

AXT delays annual meeting to June after AI-driven stock jump

15 May 2026
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized common shares to 120 million from 70 million. Shares closed at $123.78, up 7.65%, after a volatile session. China’s export controls on indium phosphide remain a key risk for AXT’s business.
Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

15 May 2026
Hyperscale Data plans a tender offer to buy up to $5 million of Class A shares at $0.21 each, above the last GPUS trade at $0.146. The company reported a preliminary first-quarter net loss of about $30 million on revenue of $44 million and filed a late notice for its Form 10-Q. The offer is pending board and regulatory approval.
Go toTop